2. As of noon trading, Regeneron Pharmaceuticals ( REGN) is up $2.74 (1.6%) to $179.14 on average volume Thus far, 324,831 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 726,900 shares. The stock has ranged in price between $178.51-$180.75 after having opened the day at $180.00 as compared to the previous trading day's close of $176.40. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $16.8 billion and is part of the drugs industry. The company has a P/E ratio of 26.1, above the S&P 500 P/E ratio of 17.7. Shares are up 3.1% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Regeneron Pharmaceuticals Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.